Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results

Alan M. Polson, Steven Garrett, Norman H. Stoller, Carl L. Bandt, Philip Jerry Hanes, William J. Killoy, G. Lee Southard, Susan P. Duke, Gary C. Bogle, Connie H. Drisko, Lynn R. Friesen

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The clinical safety and effectiveness of a subgingivally delivered biodegradable drug delivery system containing either 10% doxycycline hyclate (DH), 5% sanguinarium chloride (SC) or no agent (VC) was evaluated in a 9-month multi-center trial. The study was a randomized parallel design with 180 patients who demonstrated moderate to severe periodontitis. All patients had at least two quadrants with a minimum of four qualifying pockets ≤5 mm that bled on probing. Two of the qualifying pockets were required to be ≤7 mm. At baseline and at 4 months all qualified sites were treated with the test article administered via syringe. Probing depth reduction (PDR), attachment level gain (ALG), bleeding on probing reduction (BOP), and plaque index were determined monthly. Analysis of efficacy data from the 173 efficacy-evaluable patients indicated that all treatments gave significant positive clinical changes from baseline at all subsequent timepoints. DH was superior to SC and VC in PDR at all timepoints (P ≤ 0.01 to 0.001) with a maximum reduction of 2.0 mm at 5 months. For ALG, DH was superior to VC at months 2, 3, 4, 5, 6, 8, and 9 (P ≤ 0.04 to 0.002) and superior to SC at months 5, 6, 7, 8, and 9 (P ≤ 0.01 to 0.001) with a maximum ALG of 1.2 mm at 6 months. For BOP reduction, DH was superior to VC at all time points (P ≤ 0.05) and to SC at months 3, 5, 6, 8, and 9 (P ≤ 0.03). For DH, the maximum ALG in deep (≤7 mm) pockets was 1.7 mm and PDR 2.9 mm compared to 0.8 mm and 1.6 mm, respectively for moderate (5 to 6 mm) pockets. Test articles were applied without anesthesia and no serious adverse events occurred in the trial. The results of this study indicate that 10% doxycycline hyclate delivered in a biodegradable delivery system is an effective means of reducing the clinical signs of adult periodontitis and exhibits a benign safety profile.

Original languageEnglish (US)
Pages (from-to)119-126
Number of pages8
JournalJournal of periodontology
Volume68
Issue number2
DOIs
StatePublished - Jan 1 1997

Fingerprint

Doxycycline
Periodontitis
Chlorides
Therapeutics
Hemorrhage
Safety
Chronic Periodontitis
Syringes
Drug Delivery Systems
sanguinarine
Anesthesia

Keywords

  • clinical trials
  • doxycycline/therapeutic use
  • drug delivery systems, biodegradable
  • follow-up studies
  • multi-center studies
  • periodontitis/therapy
  • sanguinarine chloride/therapeutic use

ASJC Scopus subject areas

  • Periodontics

Cite this

Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results. / Polson, Alan M.; Garrett, Steven; Stoller, Norman H.; Bandt, Carl L.; Hanes, Philip Jerry; Killoy, William J.; Southard, G. Lee; Duke, Susan P.; Bogle, Gary C.; Drisko, Connie H.; Friesen, Lynn R.

In: Journal of periodontology, Vol. 68, No. 2, 01.01.1997, p. 119-126.

Research output: Contribution to journalArticle

Polson, AM, Garrett, S, Stoller, NH, Bandt, CL, Hanes, PJ, Killoy, WJ, Southard, GL, Duke, SP, Bogle, GC, Drisko, CH & Friesen, LR 1997, 'Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results', Journal of periodontology, vol. 68, no. 2, pp. 119-126. https://doi.org/10.1902/jop.1997.68.2.119
Polson, Alan M. ; Garrett, Steven ; Stoller, Norman H. ; Bandt, Carl L. ; Hanes, Philip Jerry ; Killoy, William J. ; Southard, G. Lee ; Duke, Susan P. ; Bogle, Gary C. ; Drisko, Connie H. ; Friesen, Lynn R. / Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results. In: Journal of periodontology. 1997 ; Vol. 68, No. 2. pp. 119-126.
@article{47d82b846a44420bb38f43845815af35,
title = "Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results",
abstract = "The clinical safety and effectiveness of a subgingivally delivered biodegradable drug delivery system containing either 10{\%} doxycycline hyclate (DH), 5{\%} sanguinarium chloride (SC) or no agent (VC) was evaluated in a 9-month multi-center trial. The study was a randomized parallel design with 180 patients who demonstrated moderate to severe periodontitis. All patients had at least two quadrants with a minimum of four qualifying pockets ≤5 mm that bled on probing. Two of the qualifying pockets were required to be ≤7 mm. At baseline and at 4 months all qualified sites were treated with the test article administered via syringe. Probing depth reduction (PDR), attachment level gain (ALG), bleeding on probing reduction (BOP), and plaque index were determined monthly. Analysis of efficacy data from the 173 efficacy-evaluable patients indicated that all treatments gave significant positive clinical changes from baseline at all subsequent timepoints. DH was superior to SC and VC in PDR at all timepoints (P ≤ 0.01 to 0.001) with a maximum reduction of 2.0 mm at 5 months. For ALG, DH was superior to VC at months 2, 3, 4, 5, 6, 8, and 9 (P ≤ 0.04 to 0.002) and superior to SC at months 5, 6, 7, 8, and 9 (P ≤ 0.01 to 0.001) with a maximum ALG of 1.2 mm at 6 months. For BOP reduction, DH was superior to VC at all time points (P ≤ 0.05) and to SC at months 3, 5, 6, 8, and 9 (P ≤ 0.03). For DH, the maximum ALG in deep (≤7 mm) pockets was 1.7 mm and PDR 2.9 mm compared to 0.8 mm and 1.6 mm, respectively for moderate (5 to 6 mm) pockets. Test articles were applied without anesthesia and no serious adverse events occurred in the trial. The results of this study indicate that 10{\%} doxycycline hyclate delivered in a biodegradable delivery system is an effective means of reducing the clinical signs of adult periodontitis and exhibits a benign safety profile.",
keywords = "clinical trials, doxycycline/therapeutic use, drug delivery systems, biodegradable, follow-up studies, multi-center studies, periodontitis/therapy, sanguinarine chloride/therapeutic use",
author = "Polson, {Alan M.} and Steven Garrett and Stoller, {Norman H.} and Bandt, {Carl L.} and Hanes, {Philip Jerry} and Killoy, {William J.} and Southard, {G. Lee} and Duke, {Susan P.} and Bogle, {Gary C.} and Drisko, {Connie H.} and Friesen, {Lynn R.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1902/jop.1997.68.2.119",
language = "English (US)",
volume = "68",
pages = "119--126",
journal = "Journal of Periodontology",
issn = "0022-3492",
publisher = "American Academy of Periodontology",
number = "2",

}

TY - JOUR

T1 - Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results

AU - Polson, Alan M.

AU - Garrett, Steven

AU - Stoller, Norman H.

AU - Bandt, Carl L.

AU - Hanes, Philip Jerry

AU - Killoy, William J.

AU - Southard, G. Lee

AU - Duke, Susan P.

AU - Bogle, Gary C.

AU - Drisko, Connie H.

AU - Friesen, Lynn R.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - The clinical safety and effectiveness of a subgingivally delivered biodegradable drug delivery system containing either 10% doxycycline hyclate (DH), 5% sanguinarium chloride (SC) or no agent (VC) was evaluated in a 9-month multi-center trial. The study was a randomized parallel design with 180 patients who demonstrated moderate to severe periodontitis. All patients had at least two quadrants with a minimum of four qualifying pockets ≤5 mm that bled on probing. Two of the qualifying pockets were required to be ≤7 mm. At baseline and at 4 months all qualified sites were treated with the test article administered via syringe. Probing depth reduction (PDR), attachment level gain (ALG), bleeding on probing reduction (BOP), and plaque index were determined monthly. Analysis of efficacy data from the 173 efficacy-evaluable patients indicated that all treatments gave significant positive clinical changes from baseline at all subsequent timepoints. DH was superior to SC and VC in PDR at all timepoints (P ≤ 0.01 to 0.001) with a maximum reduction of 2.0 mm at 5 months. For ALG, DH was superior to VC at months 2, 3, 4, 5, 6, 8, and 9 (P ≤ 0.04 to 0.002) and superior to SC at months 5, 6, 7, 8, and 9 (P ≤ 0.01 to 0.001) with a maximum ALG of 1.2 mm at 6 months. For BOP reduction, DH was superior to VC at all time points (P ≤ 0.05) and to SC at months 3, 5, 6, 8, and 9 (P ≤ 0.03). For DH, the maximum ALG in deep (≤7 mm) pockets was 1.7 mm and PDR 2.9 mm compared to 0.8 mm and 1.6 mm, respectively for moderate (5 to 6 mm) pockets. Test articles were applied without anesthesia and no serious adverse events occurred in the trial. The results of this study indicate that 10% doxycycline hyclate delivered in a biodegradable delivery system is an effective means of reducing the clinical signs of adult periodontitis and exhibits a benign safety profile.

AB - The clinical safety and effectiveness of a subgingivally delivered biodegradable drug delivery system containing either 10% doxycycline hyclate (DH), 5% sanguinarium chloride (SC) or no agent (VC) was evaluated in a 9-month multi-center trial. The study was a randomized parallel design with 180 patients who demonstrated moderate to severe periodontitis. All patients had at least two quadrants with a minimum of four qualifying pockets ≤5 mm that bled on probing. Two of the qualifying pockets were required to be ≤7 mm. At baseline and at 4 months all qualified sites were treated with the test article administered via syringe. Probing depth reduction (PDR), attachment level gain (ALG), bleeding on probing reduction (BOP), and plaque index were determined monthly. Analysis of efficacy data from the 173 efficacy-evaluable patients indicated that all treatments gave significant positive clinical changes from baseline at all subsequent timepoints. DH was superior to SC and VC in PDR at all timepoints (P ≤ 0.01 to 0.001) with a maximum reduction of 2.0 mm at 5 months. For ALG, DH was superior to VC at months 2, 3, 4, 5, 6, 8, and 9 (P ≤ 0.04 to 0.002) and superior to SC at months 5, 6, 7, 8, and 9 (P ≤ 0.01 to 0.001) with a maximum ALG of 1.2 mm at 6 months. For BOP reduction, DH was superior to VC at all time points (P ≤ 0.05) and to SC at months 3, 5, 6, 8, and 9 (P ≤ 0.03). For DH, the maximum ALG in deep (≤7 mm) pockets was 1.7 mm and PDR 2.9 mm compared to 0.8 mm and 1.6 mm, respectively for moderate (5 to 6 mm) pockets. Test articles were applied without anesthesia and no serious adverse events occurred in the trial. The results of this study indicate that 10% doxycycline hyclate delivered in a biodegradable delivery system is an effective means of reducing the clinical signs of adult periodontitis and exhibits a benign safety profile.

KW - clinical trials

KW - doxycycline/therapeutic use

KW - drug delivery systems, biodegradable

KW - follow-up studies

KW - multi-center studies

KW - periodontitis/therapy

KW - sanguinarine chloride/therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=8244245754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8244245754&partnerID=8YFLogxK

U2 - 10.1902/jop.1997.68.2.119

DO - 10.1902/jop.1997.68.2.119

M3 - Article

C2 - 9058328

AN - SCOPUS:8244245754

VL - 68

SP - 119

EP - 126

JO - Journal of Periodontology

JF - Journal of Periodontology

SN - 0022-3492

IS - 2

ER -